Answers are grounded in this paper and cite their sources.
Cystic fibrosis (CF) is substantially underdiagnosed in China, and access to targeted therapy remains limited. Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy has dramatically improved survival internationally, yet none has been approved or entered clinical trials in China. A circular problem contributes to this situation: CF is not included in newborn screening programmes because it has historically been considered extremely rare in East Asian populations. Yet, fewer than 300 patients have been genetically confirmed, in part due to limited diagnostic infrastructure. Epidemiological data based on carrier frequency suggest the true affected population exceeds 17,000 individuals. Patients who receive a molecular diagnosis face additional challenges, including a CFTR variant spectrum that differs from Western populations without established theratyping pathways, and the absence of regulatory submissions for CFTR modulators. Here, we discuss three potential approaches: expanding diagnostic capacity through standardised sweat chloride testing and clinician education, building theratyping infrastructure via patient-derived organoid biobanks, and applying existing rare disease regulatory pathways to facilitate drug approval.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: